

Patient ID SA00142098	Patient Name SAMPLE REPORT, FRIFA A	Birth Date 1974-12-31	Gender F	Age 46
Order Number SA00142098	Client Order Number SA00142098	Ordering Physician CLIENT, CLIENT	Report Notes	
Account Information C7028846 DLMP Rochester		Collected 07 Feb 2021 00:00		

Rifampin Level

Date and Time of Last Dose

02/07/2021 11:00

Dose

75 mcg

Rifampin Level


57.30 mcg/mL

Test Name: Rifampin Level

Specimen Type: Serum

Time/Date of Last Dose: 02/07/2021 11:00

Dose: 75 mcg

Rifampin Level: 57.30 mcg/mL

Interpretation:

The target range for mycobacterial infections is 8 to 24 mcg/mL 2 hours after oral dose or 2 hours after the end of intravenous infusion. Samples drawn later than 2 hours after the dose will often display concentrations below the stated range.

Rifampin generally should be given as a single daily dose. If the patient is receiving 2 small daily doses, consider combining the doses and rechecking the concentration.

Rifampin absorption may be reduced by food. Take on an empty stomach if possible.

Rifampin does not have clear concentration-related toxicity and most patients tolerate concentrations above the stated range without difficulty.

Y081

Y081

Y081

Hepatic dysfunction may produce elevated rifampin concentrations. Rifampin concentrations greater than 50% above the range may warrant a dose reduction of 150 to 300 mg.

If the time of the dose and the blood draw were not accurately recorded, accurate interpretation of the concentration is not possible. Result Comment: Result is a crucial value. It is above the analytical measurable range. Drug concentrations above the therapeutic range may have adverse effects.

Specimen Type:

Serum

Y081

Comment:

The performance characteristics for this test have been validated by Advanced Diagnostic Laboratories at National Jewish Health. It has not been cleared or approved by the US Food and Drug Administration. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions. This laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA 88) as qualified to perform high complexity clinical laboratory testing.

For additional information, including test methodology, please refer to the ADx Test Directory at www.NJLabs.org

Medical Director: Steve Groshong, M.D., PhD Advanced Diagnostic Laboratories, National Jewish Health

Received: 08 Feb 2021 08:33

Reported: 08 Feb 2021 15:48

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
Y081	National Jewish Health	Advanced Diagnostic Laboratories, 1400 Jackson Street, Denver, CO 80206		